ClinicalTrials.gg
CompletedNCT03606460Updated Jun 29, 2020Results posted

A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

A Phase 3 interventional study of Ocrelizumab Dose 1 and Ocrelizumab Dose 2 and Dose 3 in Multiple Sclerosis, sponsored by Genentech, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-06-29.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
141
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Multiple Sclerosis by Hoffmann-La Roche — 6 open to participants now, 17 under way, 7 of them phase 3. Multiple Sclerosis · Hoffmann-La Roche.

Enrollment
15th of 31
141 · median 134
Started
2018
with 3 others
Phase 3
11 of 35
2 open now
Registered
12th of 35
by date

Among the 35 studies in Multiple Sclerosis by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2018, is one of 11 in phase 3, and was the 12th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

6 of the 35 studies in Multiple Sclerosis by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Multiple Sclerosis by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study is an open-label, non-randomized study to evaluate rate and severity of infusion-related reactions (IRRs) of ocrelizumab infused over a shorter time period than the approved administration rate in participants with PPMS or RMS in the United States (U.S.). Participants will be enrolled into two cohorts. Cohort 1 will examine the effect of administering ocrelizumab per a shorter infusion protocol for Dose 2 or Dose 3. This cohort will consist of patients who have already received one or two doses of ocrelizumab according to the approved infusion protocol (i.e., per the currently U.S. label) and have reported no serious IRRs and who will then receive the next infusion of ocrelizumab at a higher rate in order to deliver 600 mg over the course of approximately 2 hours. Cohort 2 will examine the effect of administering ocrelizumab per a shorter infusion protocol for the second infusion of Dose 1. This cohort will consist of ocrelizumab naïve patients who, after receiving Infusion 1/Dose 1 of ocrelizumab at the approved rate (300 mg over approximately 2.5 hours or longer) have no reported serious IRRs, will then receive the second 300-mg shorter infusion over approximately 1.5 hours.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible to receive ocrelizumab per the United States Package Insert (USPI)
  • Able to comply with the study protocol, in the investigator's judgment
  • Age 18-55 years, inclusive
  • Have a diagnosis of PPMS or RMS, confirmed per the revised 2017 McDonald criteria
  • Expanded Disability Status Scale (EDSS) score of 0 to 6.5, inclusive
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \<1% per year during the treatment period and for at least 6 months after the last dose of study treatment (per the USPI)

Exclusion criteria

Exclusion Criteria:

  • Experienced serious IRR(s)
  • History of life-threatening infusion reaction to ocrelizumab
  • Known presence of other neurological disorders
  • Pregnancy or lactation, or intention to become pregnant during the study
  • Any concomitant disease that may require chronic treatment with systemic or during the course of the study
  • Significant, uncontrolled disease, such as cardiovascular (including cardiac arrhythmia), pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine, and gastrointestinal or any other significant disease that may preclude patient from participating in the study
  • Congestive heart failure
  • Known active bacterial, viral, fungal, mycobacterial infection or other infection or any severe episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks prior to baseline visit or oral antibiotics within 2 weeks prior to baseline visit
  • History of or currently active primary or secondary immunodeficiency
  • History or known presence of recurrent or chronic infection (e.g., , syphilis, tuberculosis)
  • History of recurrent aspiration pneumonia requiring antibiotic therapy
  • History of , including solid tumors and hematological malignancies,except basal cell, in situ squamous cell carcinoma of the skin, and in situ carcinoma of the cervix of the uterus that have been excised with clear margins
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • History of alcohol or drug abuse within 24 weeks prior to enrollment
  • Receipt of a within 6 weeks prior to enrollment
  • Systemic corticosteroid therapy within 4 weeks prior to enrollment
  • to or intolerance of oral or IV corticosteroids, including IV methylprednisolone (or equivalent steroid) administered according to the country label
  • Treatment with alemtuzumab
  • Treatment with a B-cell targeted therapies other than ocrelizumab
  • Treatment with a drug that is experimental
  • Abnormal laboratory results per local laboratory standards and investigator assessment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    Cohort 1

    This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for Dose 2 or Dose 3. Participants who have already received one or two doses of ocrelizumab according to the approved infusion protocol and have reported no serious infusion-related reactions (IRRs) will be enrolled. They will then receive the next infusion of ocrelizumab (Dose 2 or Dose 3) at a dosage of 600 milligram (mg) over the course of approximately 2 hours. Dose 2 is administered at Week 24, Dose 3 is administered at Week 48 after initial infusion.

    Drug: Ocrelizumab Dose 2 and Dose 3

  • Experimental
    Cohort 2

    This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for the second infusion of Dose 1. Ocrelizumab-naïve participants will be enrolled who, after receiving Dose 1 of ocrelizumab at the approved rate have no reported serious IRRs, will then receive the second 300-mg shorter infusion over approximately 1.5 hours.

    Drug: Ocrelizumab Dose 1

Interventions

  • DrugOcrelizumab Dose 1

    300 mg infusion administered to ocrelizumab-naive participants per approved protocol (over approximately 2.5 hours or longer) as per standard of care followed by a second 300 mg shorter infusion over approximately 1.5 hours.

  • DrugOcrelizumab Dose 2 and Dose 3

    600 mg infusion of ocrelizumab administered at a shorter rate (i.e. over the course of approximately 2 hours) at Week 24 and at Week 48

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Infusion-related Reaction (IRR) Treated With 600 mg IV Ocrelizumab

    This outcome measure evaluates the occurrence of severe infusion-related reaction (IRR) with ocrelizumab 600 mg intravenously (IV) administered over the course of 2 hours. Rate and frequency of NCI CTCAE v4.0 Grade 3 and 4 IRRs

    Time frame: During or within 24 hours of administration

Secondary outcomes

  1. Percentage of Participants With IRRs

    This outcome measure evaluates the occurrence of overall IRRs with ocrelizumab either 300mg or 600mg IV infusion. Rate and frequency of NCI CTCAE v4.0 Grade 1-4 IRRs.

    Time frame: During or within 24 hours of administration

  2. Percentage of Participants With IRRs Treated With the 300 mg Shorter Dose of Ocrelizumab

    This outcome measure evaluate the occurrence of severe IRRs with ocrelizumab 300 mg administered over the course of 1.5 hours. Rate and frequency of NCI CTCAE v4.0 Grade 3-4 IRRs.

    Time frame: During or within 24 hours of administration

07

Results

Posted Jun 29, 2020

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started9546
Completed9438
Not completed18
Withdrew: Lost to follow-up18

Outcome measures

PrimaryPercentage of Participants With Infusion-related Reaction (IRR) Treated With 600 mg IV Ocrelizumab

This outcome measure evaluates the occurrence of severe infusion-related reaction (IRR) with ocrelizumab 600 mg intravenously (IV) administered over the course of 2 hours. Rate and frequency of NCI CTCAE v4.0 Grade 3 and 4 IRRs

Time frame:
During or within 24 hours of administration
Reported as:
Number · Percentage of Participants
Percentage of Participants With Infusion-related Reaction (IRR) Treated With 600 mg IV Ocrelizumab
Percentage of ParticipantsCohort 1
Percentage of Participants With Infusion-related Reaction (IRR) Treated With 600 mg IV Ocrelizumab0 (0.0 to 3.8)
SecondaryPercentage of Participants With IRRs

This outcome measure evaluates the occurrence of overall IRRs with ocrelizumab either 300mg or 600mg IV infusion. Rate and frequency of NCI CTCAE v4.0 Grade 1-4 IRRs.

Time frame:
During or within 24 hours of administration
Reported as:
Number · Percentage of Participants
Percentage of Participants With IRRs
Percentage of ParticipantsCohort 1Cohort 2
Percentage of Participants With IRRs48.4 (38.0 to 58.9)10.9 (3.6 to 23.6)
SecondaryPercentage of Participants With IRRs Treated With the 300 mg Shorter Dose of Ocrelizumab

This outcome measure evaluate the occurrence of severe IRRs with ocrelizumab 300 mg administered over the course of 1.5 hours. Rate and frequency of NCI CTCAE v4.0 Grade 3-4 IRRs.

Time frame:
During or within 24 hours of administration
Reported as:
Number · Percentage of Participants
Percentage of Participants With IRRs Treated With the 300 mg Shorter Dose of Ocrelizumab
Percentage of ParticipantsCohort 2
Percentage of Participants With IRRs Treated With the 300 mg Shorter Dose of Ocrelizumab0 (0.0 to 7.7)

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/95 (0%)0/95 (0%)46/95 (48.4%)
Cohort 20/46 (0%)0/46 (0%)7/46 (15.2%)
Most frequent other events
Most frequent other events
EventCohort 1Cohort 2
Infusion related reactionInjury, poisoning and procedural complications46/955/46
FatigueGeneral disorders1/953/46

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Total
Mean41.75 ± 8.8041.07 ± 8.7441.52 ± 8.75
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female593493
Male361248
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Total
Hispanic or Latino437
Not Hispanic or Latino8841129
Unknown325
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Total
Black or African American8816
White8635121
Multiple101
Unknown033
08

Study locations

5 sites
  • University of Colorado; Anschutz Medical Campus Department of Neurology
    Aurora, Colorado 80045, United States
  • Dragonfly Research, LLC
    Wellesley, Massachusetts 02481, United States
  • Cleveland Clinic Fndn
    Cleveland, Ohio 44195, United States
  • Ohio Health Research Institute Grant Medical Center
    Columbus, Ohio 43215, United States
  • Oklahoma Medical Research Foundation; MS Center of Excellence
    Oklahoma City, Oklahoma 73104, United States
09

References and documents

Publications

  • Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov;46:102454. doi: 10.1016/j.msard.2020.102454. Epub 2020 Aug 18. PubMed 33045496 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in May 2019, 8 months.

Results were first posted in Jun 2020, 1 year after primary completion.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 8 months is below that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2018
First posted
Jul 30, 2018
StartActual
Sep 14, 2018
Primary completionActual
May 31, 2019
CompletionActual
May 31, 2019
Results first posted
Jun 29, 2020
Last update
Jun 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03606460
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Sep 14, 2018
Primary completion
May 31, 2019
Completion
May 31, 2019
Results posted
Jun 29, 2020
Last update
Jun 29, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion